Slate Pharmaceuticals Selects OpenClinica Enterprise

Slate Pharmaceuticals Selects OpenClinica Enterprise

(Waltham, MA) Wednesday, April 27, 2011 - OpenClinica announced today that Slate Pharmaceuticals has selected the OpenClinica Enterprise clinical trials software solution to power the development of innovative men's and women's health products.

Durham, NC-based Slate is a specialty pharmaceutical company focused on the commercialization of health products for maturing men and women. Slate's current main focus is Testopel®,   a subcutaneous pellet delivery of testosterone replacement therapy for men suffering from low testosterone levels, more commonly referred to as Low T.

"Even though we are a small, specialty pharmaceutical company, it is important for us to have a robust and regulatory compliant means for conducting clinical research," said Christine Burns, Slate's Clinical Manager. "OpenClinica's flexible, open technology enables us to undertake higher quality and more efficient clinical trials that can help define important new treatments in the area of men's health."

OpenClinica Enterprise is commercial open source software for clinical trial electronic data capture (EDC) and clinical data management (CDM). It enhances the quality and speed of clinical research by leveraging open standards in an easy-to-use, hassle-free solution.

"We are enthusiastic about bringing OpenClinica Enterprise to enhance Slate's innovative work contributing to improvement in men's health," said Cal Collins, OpenClinica's CEO. "Increased transparency into clinical trial progress and more rapid access to higher quality clinical trial data are just a few of the numerous benefits we will work with Slate to realize."

About Slate Pharmaceuticals

Slate Pharmaceuticals was founded in 2007 and is headquartered near Research Triangle Park in Durham, North Carolina. The Company was founded and is led by experienced pharmaceutical executives and is focused on the acquisition, development and commercialization of products for the treatment of selected diseases and conditions of maturing men and women. The company's primary product, Testopel® is a testosterone replacement therapy utilizing specialized subcutaneous pellet delivery. For more information see

About OpenClinica®

OpenClinica enhances the productivity of clinical trials through commercial open source software. Trusted by hundreds of biopharmaceutical companies, contract research organizations, academic, and government organizations worldwide, the OpenClinica software facilitates electronic data capture and data management, increasing the speed of collection and quality of data in clinical trials. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulatory guidelines and is designed as a standards-based, extensible, and modular platform. For more information - including product downloads - visit or follow @OpenClinica on Twitter.